551 related articles for article (PubMed ID: 11351299)
21. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
23. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways.
Masuya D; Huang C; Liu D; Nakashima T; Yokomise H; Ueno M; Nakashima N; Sumitomo S
J Pathol; 2006 Apr; 208(5):724-32. PubMed ID: 16450335
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical and molecular analysis of bax, bcl-2 and p53 genes in laryngeal squamous cell carcinomas.
Fracchiolla NS; Capaccio P; Carboni N; Pagliari AV; Neri A; Ronchett D; Pruner G; Silvotti MG; Pignataro L; Buffa R; Broich G
Anticancer Res; 1999; 19(2A):1043-51. PubMed ID: 10368653
[TBL] [Abstract][Full Text] [Related]
25. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53.
Huang C; Kohno N; Inufusa H; Kodama K; Taki T; Miyake M
Am J Pathol; 1999 Sep; 155(3):955-65. PubMed ID: 10487853
[TBL] [Abstract][Full Text] [Related]
27. Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer.
Katsumata K; Sumi T; Tomioka H; Aoki T; Koyanagi Y
Int J Clin Oncol; 2003 Dec; 8(6):352-6. PubMed ID: 14663636
[TBL] [Abstract][Full Text] [Related]
28. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
[TBL] [Abstract][Full Text] [Related]
29. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
30. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Sturm I; Köhne CH; Wolff G; Petrowsky H; Hillebrand T; Hauptmann S; Lorenz M; Dörken B; Daniel PT
J Clin Oncol; 1999 May; 17(5):1364-74. PubMed ID: 10334520
[TBL] [Abstract][Full Text] [Related]
32. Bax, Bcl-2, and p53 expression in endometrial cancer.
Sakuragi N; Salah-eldin AE; Watari H; Itoh T; Inoue S; Moriuchi T; Fujimoto S
Gynecol Oncol; 2002 Sep; 86(3):288-96. PubMed ID: 12217750
[TBL] [Abstract][Full Text] [Related]
33. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.
Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
Cancer Lett; 2004 Jul; 210(2):151-7. PubMed ID: 15183530
[TBL] [Abstract][Full Text] [Related]
34. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
35. Mutations of p53 in thyroid carcinoma with an insular component.
Takeuchi Y; Daa T; Kashima K; Yokoyama S; Nakayama I; Noguchi S
Thyroid; 1999 Apr; 9(4):377-81. PubMed ID: 10319944
[TBL] [Abstract][Full Text] [Related]
36. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
Letsas KP; Frangou-Lazaridis M; Skyrlas A; Tsatsoulis A; Malamou-Mitsi V
Pathol Int; 2005 Nov; 55(11):694-702. PubMed ID: 16271081
[TBL] [Abstract][Full Text] [Related]
37. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
[TBL] [Abstract][Full Text] [Related]
39. Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas.
Yagi OK; Akiyama Y; Nomizu T; Iwama T; Endo M; Yuasa Y
Gastroenterology; 1998 Feb; 114(2):268-74. PubMed ID: 9453486
[TBL] [Abstract][Full Text] [Related]
40. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas.
Pollina L; Pacini F; Fontanini G; Vignati S; Bevilacqua G; Basolo F
Br J Cancer; 1996 Jan; 73(2):139-43. PubMed ID: 8546897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
